Tanvex BioPharma Inc (6541) - Total Liabilities

Latest as of March 2026: NT$2.27 Billion TWD ≈ $71.64 Million USD

Based on the latest financial reports, Tanvex BioPharma Inc (6541) has total liabilities worth NT$2.27 Billion TWD (≈ $71.64 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Tanvex BioPharma Inc annual equity growth to track the company's year-over-year net asset growth rate.

Tanvex BioPharma Inc - Total Liabilities Trend (2013–2025)

This chart illustrates how Tanvex BioPharma Inc's total liabilities have evolved over time, based on quarterly financial data.

Tanvex BioPharma Inc Competitors by Total Liabilities

The table below lists competitors of Tanvex BioPharma Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Tibet Galaxy Science & Technology Development Co Ltd SHE:000752	China	CN¥257.35 Million
ALTYNGOLD PLC LS -10 F:FPP0	Germany	€65.07 Million
Fiera Capital Corporation TO:FSZ	Canada	CA$956.48 Million
Wuhan Tianyu Info Industry SHE:300205	China	CN¥662.77 Million
Forrestania Resources Ltd AU:FRS	Australia	AU$44.70 Million
Jiangsu Wanlin Modern Logistic SHG:603117	China	CN¥317.29 Million
CapMan Oyj B HE:CAPMAN	Finland	€155.63 Million
Portillo's Inc NASDAQ:PTLO	USA	$1.12 Billion

Liability Composition Analysis (2013–2025)

This chart breaks down Tanvex BioPharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 6541 market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.33	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.42	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.30	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Tanvex BioPharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Tanvex BioPharma Inc (2013–2025)

The table below shows the annual total liabilities of Tanvex BioPharma Inc from 2013 to 2025.

Year	Total Liabilities	Change
2025-12-31	NT$2.27 Billion ≈ $71.43 Million	+23.09%
2024-12-31	NT$1.84 Billion ≈ $58.03 Million	-5.17%
2023-12-31	NT$1.94 Billion ≈ $61.19 Million	-4.24%
2022-12-31	NT$2.03 Billion ≈ $63.90 Million	+5.71%
2021-12-31	NT$1.92 Billion ≈ $60.45 Million	+9.52%
2020-12-31	NT$1.75 Billion ≈ $55.20 Million	+223.18%
2019-12-31	NT$542.12 Million ≈ $17.08 Million	+105.41%
2018-12-31	NT$263.92 Million ≈ $8.31 Million	+17.93%
2017-12-31	NT$223.78 Million ≈ $7.05 Million	-25.22%
2016-12-31	NT$299.25 Million ≈ $9.43 Million	+146.47%
2015-12-31	NT$121.41 Million ≈ $3.83 Million	+86.52%
2014-12-31	NT$65.09 Million ≈ $2.05 Million	-22.16%
2013-12-31	NT$83.63 Million ≈ $2.63 Million	--

About Tanvex BioPharma Inc

TW:6541 Taiwan Biotechnology

Market Cap

$311.40 Million

NT$9.88 Billion TWD

Market Cap Rank

#14484 Global

#594 in Taiwan

Share Price

NT$37.30

Change (1 day)

+1.91%

52-Week Range

NT$36.60 - NT$65.30

All Time High

NT$287.73